.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, people with metastatic gastrointestinal tumors that obtained biomarker-matched treatments based upon flowing lump DNA profiling revealed a better clinical perk than those receiving unmatched treatment.